After artemisinin: searching for the next front-line malaria drug It's been decades since the last new antimalarial drug was developed. More are … ...

Many people believe the malaria treatment artemisinin may also fight cancer. Get the facts.

The anti-malarial drug Artemisinin is highly effective. It's critical for kids, who are especially vulnerable. A new study comes to an alarming conclusion.

Artemisinin raises hopes and fears amid COVID-19 Researchers test Artemisia annua extracts against the novel coronavirus, while the WHO cautions that herbal remedies made from the plant could ...

Artemisinin, a compound in the sweet wormwood plant, may have potential in future cancer treatments. Research is still underway. This article looks at recent investigations into artemisinin and ...

Artemisinin as a Natural Anticancer: Here's Why To Go To Tijuana, Mexico For This Alternative Treatment Chemotherapy, radiation, invasive surgery, and other types of conventional cancer solutions are ...

One of the most widely-used anti-malaria drugs, artemisinin, no longer works on a strain spreading in parts of southeast Asia ...

Three-day therapeutic courses are losing their efficacy against malarial parasites in the Greater Mekong Subregion. But continued rational and strategic use of artemisinin combination treatments is ...

Artemisinin-based combination therapies - known for short as ACTs - are recommended by the WHO against malaria, especially those types now resistant to chloroquine, which is one of the main drug ...

Artemisinin derivatives have become the first-line treatments for uncomplicated and severe malaria with improved mortality, side effect profiles and accessibility.

Artemisinin has not been met with widespread parasite resistance, and WHO warns that if such resistance developed "the public health consequences could be dire, as no alternative antimalarial ...

Artemisinin is one of the few antimalarials for which there is no widespread resistance. However, malaria parasites with decreased sensitivity have been reported recently. In this Review Arjen ...